Vildagliptin+ Metformin Hydrochloride
The active substances of Anvildis Duo are vildagliptin and metformin, which belong to the group of oral antidiabetic medications.
Anvildis Duo is used to treat adult patients with type 2 diabetes. This type of diabetes is also known as non-insulin-dependent diabetes. Anvildis Duo is used when diet and exercise alone are not enough to control diabetes, and it can be taken with other diabetes medications (insulin or sulfonylureas).
Type 2 diabetes is a condition where the body does not produce enough insulin or the insulin produced by the body does not work properly. Type 2 diabetes can also occur when the body produces too much glucagon.
Both insulin and glucagon are produced in the pancreas. Insulin helps lower blood sugar levels, especially after meals. Glucagon is a substance that stimulates the production of sugar in the liver and increases blood sugar levels.
Both active substances, vildagliptin and metformin, help control blood sugar levels. Vildagliptin works by stimulating the pancreas to produce insulin and reducing the production of glucagon. Metformin helps the body use insulin better. It has been shown that the medication lowers blood sugar levels, which can help prevent complications of diabetes.
Anvildis Duo may cause a very rare but very serious side effect called lactic acidosis, especially if the patient has kidney problems. The risk of lactic acidosis also increases in cases of uncontrolled diabetes, severe infection, prolonged fasting, or alcohol consumption, dehydration (see more information below), liver disease, or any conditions where a part of the body is not getting enough oxygen (e.g., severe heart disease).
If any of these conditions apply to the patient, they should consult their doctor for more detailed instructions.
A condition that may lead to dehydration(significant loss of water from the body), such as severe vomiting, diarrhea, fever, exposure to high temperatures, or if the patient drinks less fluid than usual. The patient should consult their doctor for more detailed instructions.
Lactic acidosis, as it can lead to coma.
Symptoms of lactic acidosis include:
Lactic acidosis is a life-threatening condition that requires immediate medical attention.
Anvildis Duo does not replace insulin. Therefore, it should not be used to treat type 1 diabetes.
Before starting Anvildis Duo, the patient should discuss it with their doctor, pharmacist, or nurse if they have or have had pancreatitis.
Before starting Anvildis Duo, the patient should consult their doctor, pharmacist, or nurse if they are taking a diabetes medication called a sulfonylurea. The doctor may want to reduce the dose of the sulfonylurea taken with Anvildis Duo to avoid low blood sugar (hypoglycemia).
If the patient has previously taken vildagliptin but had to stop due to liver disease, they should not take this medication.
Diabetic skin changes are a common complication of diabetes. The patient should follow the doctor's or nurse's advice on skin and foot care. It is also recommended that the patient pay special attention to the occurrence of new blisters or ulcers while taking Anvildis Duo. If they occur, the patient should consult their doctor promptly.
If the patient is to undergo major surgery, they should not take Anvildis Duo during or for some time after the surgery. The doctor will decide when the patient should stop and restart Anvildis Duo.
Before starting treatment with Anvildis Duo and at three-month intervals during the first year of treatment, and periodically thereafter, the patient should undergo liver function tests. This will help detect any signs of increased liver enzyme activity as soon as possible.
During treatment with Anvildis Duo, the doctor will monitor the patient's kidney function at least once a year or more frequently if the patient is elderly and/or has worsening kidney function.
The doctor will regularly assess the patient's blood and urine sugar levels.
Anvildis Duo is not recommended for children and adolescents under 18 years of age.
If the patient is to receive an iodine-containing contrast agent intravenously, for example, for an X-ray examination or computed tomography, they should stop taking Anvildis Duo before or at the latest at the time of the injection. The doctor will decide when the patient should stop and restart Anvildis Duo.
The patient should tell their doctor about all medications they are currently taking or have recently taken, as well as any medications they plan to take. The patient may require more frequent blood sugar checks or kidney function tests, or the doctor may need to adjust the dose of Anvildis Duo. It is especially important to inform about the following medications:
The patient should avoid consuming excessive amounts of alcohol while taking Anvildis Duo, as this may increase the risk of lactic acidosis (see section "Warnings and Precautions").
Before taking any medication, the patient should consult their doctor or pharmacist.
If the patient experiences dizziness while taking Anvildis Duo, they should not drive or operate machinery.
The dose of Anvildis Duo varies depending on the patient's condition. The doctor will determine the dose of Anvildis Duo to be taken.
This medication should always be taken as directed by the doctor. In case of doubts, the patient should consult their doctor or pharmacist.
The recommended dose is one 50 mg + 850 mg or 50 mg + 1000 mg film-coated tablet taken twice a day.
If the patient has kidney problems, the doctor may prescribe a lower dose. If the patient is taking a diabetes medication called a sulfonylurea, the doctor may also prescribe a lower dose.
The doctor may prescribe this medication alone (monotherapy) or with other medications that lower blood sugar levels.
The patient should continue to follow their doctor's dietary advice while taking Anvildis Duo. Following a diet is especially important when the patient is on a weight-control diet.
In case of accidental ingestion of too many Anvildis Duo tablets or if someone else has taken them, the patient should immediately inform their doctor or pharmacist. The patient may require medical attention. If it is necessary to visit a doctor or hospital, the patient should take the medication packaging and package leaflet with them.
If the patient forgets to take a tablet, they should take it with their next meal, unless it is almost time for their next dose. The patient should not take a double dose (two tablets at once) to make up for a missed tablet.
To maintain control of blood sugar levels, the medication should be taken for as long as the doctor recommends. The patient should not stop taking Anvildis Duo without their doctor's advice. If the patient has any questions about how long to take Anvildis Duo, they should consult their doctor.
In case of any further doubts about taking this medication, the patient should consult their doctor, pharmacist, or nurse.
Like all medications, Anvildis Duo can cause side effects, although not everyone will experience them.
The patient should stop taking Anvildis Duo and seek medical attention immediatelyif they experience any of the following side effects:
In some patients taking vildagliptin and metformin, the following side effects have occurred:
In some patients taking vildagliptin and metformin and a sulfonylurea, the following side effects have occurred:
In some patients taking vildagliptin and metformin and insulin, the following side effects have occurred:
After the medication was placed on the market, the following side effects have also been reported:
If the patient experiences any side effects, including those not listed in this package leaflet, they should inform their doctor, pharmacist, or nurse.
Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309, Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medication.
The medication should be stored out of sight and reach of children.
Do not use this medication after the expiry date stated on the blister and carton after "EXP" / "Expiry Date (EXP)". The expiry date refers to the last day of the month stated.
Store in a temperature below 25°C.
Store in the original packaging to protect from moisture.
Do not use this medication if there are any signs of damage or tampering with the packaging.
Medications should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medications they no longer use. This will help protect the environment.
Anvildis Duo, 50 mg + 850 mg, film-coated tablets
Yellow, oval film-coated tablets with a nominal length of 20.1 mm and a nominal width of 8.1 mm, with "MLV" embossed on one side and smooth on the other.
Anvildis Duo, 50 mg + 1000 mg, film-coated tablets
Dark yellow, oval film-coated tablets with a nominal length of 21.1 mm and a nominal width of 9.1 mm, with "MHV" embossed on one side and smooth on the other.
Blister pack of OPA/Aluminum/PVC/Aluminum foil.
Anvildis Duo is available in packs containing 10, 30, 60 film-coated tablets in a cardboard box.
Not all pack sizes may be marketed.
Vipharm S.A.
A. and F. Radziwiłłów Street 9
05-850 Ożarów Mazowiecki
tel.: +48 22 679 51 35
fax: +48 22 678 92 87
e-mail: vipharm@vipharm.com.pl
Adipharm EAD
130, Simeonovsko shose Blvd.,
1700 Sofia
Bulgaria
Genepharm S.A.
18th km Marathonos Avenue,
153 51 Pallini Attiki
Greece
Hungary
Anvildis Duo 50 mg/850 mg film-coated tablets
Anvildis Duo 50 mg/1000 mg film-coated tablets
Slovakia
Anvildis Duo 50 mg/850 mg
Anvildis Duo 50 mg/1000 mg
Poland
Anvildis Duo
Czech Republic
Anvildis Duo
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.